Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5472985A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 2, 1994 |
| Grant date | Dec 5, 1995 |
| Priority date | — |
| Expiry date | Sep 2, 2014 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/323
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.